
As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

Neurology News Network for the week ending November 14th, 2026. [WATCH TIME: 6 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.

At a NeurologyLive Clinical Forum in Philadelphia, Pennsylvania, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

At a NeurologyLive Clinical Forum, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how patients with NF1-associated plexiform neurofibromas get recognized, referred, and treated.

As treatment options for generalized myasthenia gravis continue to expand, Ali Habib, MD, explores how clinicians can refine therapeutic decisions to prioritize sustained disease control, patient function, and quality of life.

The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.

Following the release of phase 3 NIMBLE findings, Ali Habib, MD, examines the clinical significance of cemdisiran's MG-ADL results alongside key safety and tolerability considerations.

GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.

The professor of medicine at McMaster University discussed the significance of asundexian’s approval, how a stroke-specific dose-finding approach shaped its development, and what OCEANIC-STROKE showed. [WATCH TIME: 6 minutes]

In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.

The professor of medicine at McMaster University discussed the FDA approval of asundexian, why secondary prevention of noncardioembolic stroke has lagged behind, and the phase 3 OCEANIC-STROKE trial. [WATCH TIME: 5 minutes]

At a NeurologyLive Clinical Forum in New York, Mary Ann Picone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.

Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton discussed a recent analysis of the PROSPECT trial of using transcutaneous afferent patterned stimulation in essential tremor. [WATCH TIME: 5 minutes]

An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.

The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discusses how NMAC will identify its 2027 priorities through community feedback on care access, research, and disability rights. [WATCH TIME: 3 minutes]

The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

Interim phase 1b data showed that cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discusses NMAC's transition toward year-round collaboration and its role in advancing neuromuscular research, treatment access, and care. [WATCH TIME: 3 minutes]

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.